Investigation of Naltrexone for Pathological Gambling
The investigators plan to investigate the safety, tolerability, and efficacy of the opioid antagonist naltrexone in Pathological Gambling. We hypothesize that naltrexone will be superior to placebo in reducing gambling urges and behavior, when combined with adjuvant non-pharmacological treatment as usual.
Pathological gambling (PG) is a significant public health problem that can cause significant devastation for the individuals affected and their families. Those afflicted may experience unemployment, considerable debt, marital problems, family dysfunction, legal troubles, incarceration, and mental health issues including suicidality. Prevalence estimates vary but most estimates put it at between 1% and 2%, with annual costs of over $5 billion in the United States alone. Thus, PG is costly not only for the affected individuals and their families, but also for society in general.
The current treatment as usual for PG is limited to various types of counseling, psychotherapy (e.g. cognitive behavioral therapy), and self-help groups such as Gamblers Anonymous. However, such treatment modalities have not been shown to be particularly effective. High rates or relapse are common and treatment attrition is often a concern.
Currently, no drugs are approved by the U.S. Food and Drug Administration for the treatment of PG. Pharmacological treatment studies are still in their infancy but show considerable promise. Several placebo-controlled, randomized clinical trials have been conducted, but results have been limited by small sample sizes, short durations, exclusion of individuals with co-occurring disorders, and heterogeneity in treatment response measures and diagnostic criteria used for inclusion.
Selective serotonin reuptake inhibitors (SSRIs) have shown mixed results in PG. Some studies have suggested a benefit of active drug over placebo while other studies have not. Mood stabilizers have not been extensively studied but some reports suggest that certain patients, such as those with co-morbid bipolar spectrum disorders, may benefit from this type of medication. Atypical antipsychotics have also been tried with limited success and may be more appropriate for patients with co-occurring psychotic disorders.
Opioid antagonists such as naltrexone and nalmefene, possibly through their modulation of the mesolimbic dopamine system, have demonstrated preliminary efficacy superior to placebo in treating PG. As with substance use disorders (SUD), it has been suggested that opioid antagonists may exert their therapeutic benefit by helping to reduce the appetitive urges or cravings present in symptomatology of addiction.
From the neurochemical perspective, the pharmacological action of opioid antagonists is to block the effects of endogenous endorphins on mu-opioid receptors and may inhibit dopamine release in the nucleus accumbens. The mu-opioid system is generally thought to be involved in the mediation of hedonic, rewarding and reinforcing behaviors. The mu-opioid and mesolimbic pathways have been implicated in PG. For example, problem gamblers have been shown to have elevated levels of the endogenous opioid β-endorphin during gambling (Shinohara et al 1999).
Naltrexone, a pure opioid antagonist, is an FDA-approved medication with two labeled indications. Firstly, for the blockade of the effects of exogenously administered opioids. And secondly, for the treatment of alcohol dependence. However, it's labeling is clear that it has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for addiction. Naltrexone has been investigated in PG in part due to its proposed ability to modulate the mesolimbic dopamine pathway. In preliminary studies, it has shown efficacy superior to placebo. As with clinical trials of alcohol dependence, it appears that naltrexone targets craving and urge states. In fact, naltrexone has shown to be particularly effective in individuals with stronger urges to gamble at treatment onset.
A double-blind, placebo-controlled twelve-week investigation of naltrexone in 83 subjects (of which 45 were used for analysis) has been described(Kim et al 2001). Doses were initiated at 25 mg/day and titrated to a maximum dosage of 250 mg/day, with an average final dose of 187.50 mg/day (SD=96.45). Naltrexone was superior to placebo and was associated with statistically significant improvement in various measures of gambling severity, both self-reported and clinician-administered. A post hoc analysis showed that naltrexone was more effective in gamblers who reported more severe urges.
More recently, an eighteen-week double-blind, placebo-controlled study of naltrexone for PG was reported(Grant et al 2008). Following a single-blinded one-week placebo lead-in, seventy-seven PG subjects were randomized to daily doses of 50mg, 100mg, or 150mg naltrexone. Unlike the previous shorter naltrexone study, this group included subjects with a range of co-occurring disorders. Outcomes did not significantly differ among the three dosages. The three active arms of the study were combined and compared to placebo. Analyses showed that naltrexone was more effective than placebo in decreasing PG severity, gambling urges, gambling behavior, and psychological functioning.
Nalmefene hydrochloride is a similar-acting opioid antagonist. Contrary to naltrexone, nalmefene is not associated with possible liver toxicity. A sixteen-week multicenter, randomized, dose-ranging, double-blind, placebo-controlled investigation was conducted at 15 outpatient treatment centers in the U.S., including at Yale(Grant et al 2006). Two hundred and seven male and female subjects were randomized to either 25mg, 50 mg, 100mg per day or to an equivalent placebo. All three active arms began with a one-week course of 25mg per day. This study did not include individuals with co-occurring disorders. Subjects assigned to the active arms showed statistically significant reductions in gambling severity. The 50mg and 100mg doses resulted in intolerable side effects. It appears that the lower 25mg dose was the most efficacious. In fact, the 25mg dose was unique in terms of demonstrating superiority to placebo based on overall response to treatment as measures by the Clinical Global Impression (CGI) improvement scale.
Based on previous encouraging results both at Yale and elsewhere, this study will attempt to replicate and extend the safety, tolerability, and efficacy findings of opioid antagonists in the management of PG. In addition, this study will provide much needed information regarding pharmacotherapy in conjunction with treatment as usual for PG.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Connecticut DMHAS Problem Gambling Services and Bettor Choice Programs
Results (where available)
- Source: http://clinicaltrials.gov/show/NCT01057862
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.
An activity distinguished primarily by an element of risk in trying to obtain a desired goal, e.g., playing a game of chance for money.
An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.
In statistics, a technique for numerically approximating the solution of a mathematical problem by studying the distribution of some random variable, often generated by a computer. The name alludes to the randomness characteristic of the games of chance played at the gambling casinos in Monte Carlo. (From Random House Unabridged Dictionary, 2d ed, 1993)
This study assessed whether naltrexone, an opioid antagonist, might be effective in reducing excessive gambling behavior in people who also drink heavily. The efficacy of naltrexone was ev...
The purpose of this study is to determine if nalmefene is safe and effective in the treatment of pathological gambling.
The goal of the proposed study is to evaluate the efficacy and safety of the drug memantine in individuals with pathological gambling (PG). Thirty subjects with DSM-IV PG will receive 10 w...
Pathological gambling (PG) is characterized by a persistent pattern of continued gambling behavior despite its adverse consequences. PG is a chronic, progressive, male-dominated disorder,...
The goal of the proposed study is to evaluate the efficacy and safety of tolcapone in pathological gambling.
Pathological gambling is defined as inappropriate, persistent, and maladaptive gambling behaviour. It is a non-pharmacological addiction classified as an impulse control disorder. However, pathologica...
Background/Aims: Only a small percentage of pathological gamblers utilizes professional treatment for gambling problems. Little is known about which social and gambling-related factors are associated...
Most research on the assessment, epidemiology, and treatment of problem gambling has occurred in Western jurisdictions. This potentially limits the cross-cultural validity of problem gambling assessme...
This paper aims to explore the features of the spread of gambling and its pathological outcomes among women, through a review of the existing literature. It analyzes 73 documents, published between 19...